Patience through the early titration phase pays off with accelerating results as doses increase
Emil Kongshj Larsen, executive vice president of international operations at Novo Nordisk, said in a press release, This approval is another important step in helping people living with obesity reach very significant weight loss
Since its discovery in 1984 by Svetlana Mosjov, GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly become cornerstone treatments for type 2 diabetes mellitus (T2DM) and obesity
In mouse studies, PTD-DBM promoted hair regrowth in alopecia models and demonstrated the ability to stimulate new follicle formation, something most treatments cannot do
It's one of the few structures in the human body that, once damaged, is severely limited in its ability to repair itself [21]